Hand‐foot‐skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics

• Published in: Pediatric dermatology Vol. 35; no. 4; pp. e206 - e209
• Main Authors: Kusari, Ayan, Borok, Jenna, Han, Allison M., Valderrama, Alix Jessika, Friedlander, Sheila Fallon
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2018
• Subjects: Cancer; Case reports; Chemotherapy; Child; Children; Diagnosis, Differential; Feet; Fluocinolone Acetonide - therapeutic use; Glucocorticoids - therapeutic use; Hand-Foot Syndrome - diagnosis; Hand-Foot Syndrome - drug therapy; hand‐foot skin reaction; Humans; hyperkeratotic lesions; Inhibitor drugs; keratolytics; Male; multikinase inhibitors; Niacinamide - adverse effects; Niacinamide - analogs & derivatives; Orthotic Devices - adverse effects; Pediatrics; Phenylurea Compounds - adverse effects; Protein Kinase Inhibitors - adverse effects; Skin; sorafenib; Targeted cancer therapy; topical corticosteroids; Tumors; hyperkeratotic lesions; multikinase inhibitors; hand-foot skin reaction; sorafenib; topical corticosteroids; keratolytics
• ISSN: 0736-8046; 1525-1470
• DOI: 10.1111/pde.13523

Hand‐foot‐skin reaction is a distinct clinical condition arising in association with the use of multikinase inhibitors, including sorafenib. Because multikinase inhibitors are increasingly being used in children with cancer, recognition of this previously unfamiliar condition is of importance to pediatric dermatologists. We describe the diagnosis and successful treatment of a case of hand‐foot‐skin reaction in a child taking sorafenib for an unresectable desmoid tumor.